

Βιογραφικό Σημείωμα καθ. Ουρανίας Δαφνή

Ουρανία Δαφνή	Καθηγήτρια Βιοστατιστικής, Σχολή Επιστημών Υγείας, Τμήμα Νοσηλευτικής, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Ελλάδα		
Ίδρυμα και Τοποθεσία	Δίπλωμα	Χρονιά	Πεδίο Μελέτης
Harvard School of Public Health, Boston, USA	Sc.D.	1993	Βιοστατιστική
University of Minnesota, Minneapolis, USA	M.Sc.	1988	Στατιστική
University of Minnesota, Minneapolis, USA	M.Sc.	1988	Βιομηχανική Μηχανική
Πανεπιστήμιο Πατρών, Πάτρα, Ελλάδα	B.Sc.	1982	Μηχανολόγος Μηχανικός

Ακαδημαϊκές Θέσεις

CHUV, Department of Oncology, UNIL, Lausanne, Switzerland
- Professeure Invitée, 2018-2024

School of Health Sciences, Department of Nursing, National and Kapodistrian University of Athens, Greece
- Professor of Biostatistics, 2010-present, Associate Professor, 2004-2009, Assistant Professor, 1998-2003
- Director of Public Health Division, 2022-present
- Director, Laboratory of Biostatistics, 2003-present

Department of Statistics and Operations Research, Technical University of Catalonia, Spain
- Visiting Professor, 2011

Department of Biostatistics, Harvard School of Public Health, USA
- Visiting Scientist, June-August 2000

Τμήμα Στατιστικής, Οικονομικό Πανεπιστήμιο Αθηνών, Ελλάδα
- Διδάσκουσα με σύμβαση, 1995-1997

Department of Biostatistics, Harvard School of Public Health, USA
- Research Associate, Neurology Section Head, Statistical and Data Analysis Center, 1993-1995

Επαγγελματική Εμπειρία, Τμητικές Θέσεις και Βραβεία***ESMO***

Member of the ESMO Cancer Medicines Committee, 2021-2022, 2023-2024, 2025-2026
Member of the Task Force on Magnitude of Clinical Benefit Scale, 2013-2015; 2016-2018; 2019-2022
Faculty, Principles of Clinical Trials and Systemic Therapy, 2012-2014; 2015-2017; 2018-2021
Faculty, Educational Workshops: Beijing 2012; Shanghai 2012; Damam 2013; Vienna 2015; Lima 2015-2018
Faculty, ESMO-ESO Masterclass: Berlin 2019; Virtual 2021
Official Research Partner of the W4O study (2018-present)

ASCO

Member of the Central and Eastern Europe Regional Council, 2022-present
International Clinical Trials Workshop (ICTW) Working Group Member, 2017-2020
Scientific Program Committee Member – Biostatistics Track, 2013-2016
Faculty, ICTW Workshop, Cluj, Romania, 2016

European Thoracic Oncology Platform (ETOP), www.etop-eu.org

Scientific Committee Member, 2021-present

Group Statistician 2011-present

Statistics Track Chair, Lungscape Steering Committee, 2011-present

Faculty, 13 Residential Workshops: Lugano 2012, 2013; Gdansk 2014; Amsterdam 2015-2017; Barcelona 2018; Amsterdam 2019; virtual 2020; Barcelona 2021; Amsterdam 2022; Zurich 2023, Barcelona 2024

Υπουργείο Υγείας

Μέλος ΔΣ, ΚΕΛΠΝΟ, 2015-2019

Επιστημονικός Διευθυντής Εθνικού Προγράμματος Εποπτείας του Ολυμπιακού Συνδρόμου, 2002-2004

Σύμβουλος του Προέδρου για θέματα Βιοστατιστικής και Επιδημιολογικής Επιτήρησης, ΚΕΛΠΝΟ, 2002-2004

Αντιπρόεδρος, Επιτροπή Βιοϊσοδυναμίας, ΕΟΦ, 1999-2001

International Biometric Society (IBS)

IBS Governance - Representative Council Member, 2017-2021

Education Committee Member, 2010-2016

Editorial Representative, Executive Committee Member, 2007-2011

President, Eastern Mediterranean Region, 2005-2007

Publicity Officer, Eastern Mediterranean Region, 2001-2004

Biometric Bulletin Editor for IBS (2005-2008; 2008 Recognition Award),

Frontier-Science and Technology Research Foundation (FSTRF), Boston, MA, USA, www.fstrf.org

Member of the Board of Directors, 2008-present

Vice-President & Director, Frontier Science Foundation – Hellas, 2007-present, www.frontier-science.gr

Other Professional Activities

EHA-CRTH – Faculty 2023, 2024, 2025

Swiss National Science Foundation (SNSF), IICT Evaluation Panel Member, Statistical Referee 2020-2022

ESO - Certificate of Advanced Studies in Lung Cancer, Lecturer/Speaker, 2018-2021

NCI Center for Global Health, Head and Neck Cancer International Group (HNCIG), Protocol and Endpoints Committee Member, 2017-2020

National Spanish Network of Biostatistics (BiostatNet), International Advisory Committee Member, since 2012

IDMC Member – ETNA trial, PEARL trial, Fondazione Michelangelo, 2013-2016; 2015-2021

Department of Biostatistics, Harvard School of Public Health, Member of the Alumni Award Committee, 2003-2006

Ελληνική Στατιστική Υπηρεσία, Μέλος της Επιτροπής Βραβείων Διατριβής Λευκοπούλου, 2005-2007

Συντακτικές

Editor: IBS Biometric Bulletin, 2005-2008

Editorial Board Member: Cancer Treatment Reviews, 2024; ESMO Open - Cancer Horizons, since 2015; Lung Cancer, since 2013; Advances in Disease Surveillance, 2006-2009

Διοργάνωση Διεθνών Συνεδρίων

International Scientific Committee: IBC2018 Barcelona; IBC2020 Kobe

Chair: 3rd EMR-IBS Conference, 2005, Corfu, Greece; 6th EMR-IBS Conference, 2011, Crete, Greece;

9th EMR-IBS Conference, 2017, Thessaloniki, Greece;

Βραβεία

Βραβείο Αναγνώρισης από την International Biometric Society, 2008; Βραβείο Βασιλείου Μαλάμου από Πανεπιστήμιο Αθηνών, 2003; Βραβείο Λευκοπούλου από Ελληνική Στατιστική Υπηρεσία, 1995; Βραβείο από Drug Information Association, 1993; Φοιτητικό Βραβείο, Eastern North American Region, IBS, 1993

Πρόσφατη/Τρέχουσα Έρευνα σε Κλινικές Δοκιμές

- ETOP-sponsored trials: 2012-present
EMPHASIS, randomized phase III; BELIEF, phase II; SPLENDOR (ETOP/EORTC), randomized phase III; STIMULI, randomized phase II; NICHE, Phase II; NICOLAS, Phase II; PEARLS (ETOP/EORTC), randomized phase III; ALERT-lung, Phase II; PROMISE-MESO, randomized phase III; BOOSTER, randomized phase II; BEAT-meso, randomized phase III; CHESS, phase II; ABC-lung, randomized phase II; STEREO phase II; AMAZE-lung phase II; USZ-STRIKE phase III; ADEPPT phase II; RAISE phase II; more trials under development
- ETOP-sponsored Lungscape project and corresponding retrospective studies. 2011-present
- ETOP-sponsored Mesoscape project and corresponding retrospective studies. 2019-present
- CHUV-sponsored trials: 2015-present
RACIN, Phase I; ATATIL, Phase I; LuMED, Phase I; PC_OC-DC, Phase Ib; NIVO71, retrospective study; CyberImmunoBreast, Phase II; SolTIL, phase Ib; NeoTIL phase Ib/II, phase I, PEP_DC pancreatic, phase I; 6 trials under development
- ALTTO translational research projects, Statistical Subcontract, 2020-2022
- TransHERA: The Translational Research project of the Phase III multicenter HERA (Herceptin Adjuvant) trial of the Breast International Group (BIG), Statistical Subcontract, 2009-2016.

PUBMED LINK: <http://www.ncbi.nlm.nih.gov/pubmed/?term=dafni+u+or+dafni+o+or+dafni+r>
https://scholar.google.com/citations?user=TwlN_xAAAAAJ&hl=th

Αριθμός Δημοσιεύσεων με h-index: 70

Επιλεγμένες Δημοσιεύσεις και Παρουσιάσεις (peer reviewed) από το 2019 έως το 2024

Cherny NI, de Vries EGE, Dafni U, Garrett-Mayer E, McKernin SE, Piccart M, Latino NJ, Douillard JY, Schnipper LE, Somerfield MR, Bogaerts J, Karlis D, Zygoura P, Vervita K, Pentheroudakis G, Tabernero J, Zielinski Ch, Wollins DS, Schilsky RL. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. **J Clin Oncol 2019; 37 (4): 336-349.**

Peters S, Dafni U, Boyer M, De Ruyscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino MC. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). **Ann Oncol. 2019; 30 (2): 161-165.**

Dzadzadzuszko R, Smit EF, Dafni U, Wolf J, Wasag B, Biernat W, Finn SP, Kammiller R, Tsourtis Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters S. Afatinib in non-small cell lung cancer with HER2

mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP). *J Thorac Oncol.* 2019; pii: S1556-0864(19)30148-0.

Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, et al; Lungscape Consortium.

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. *Lung Cancer* 2019; 131: 95-103.

Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Veas H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguat AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer – The ETOP NICOLAS trial. *Lung Cancer* 2019; 133: 83-87.

Dafni U, Tsourti Z, Vervita K, Peters S. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. *Lung Cancer* 2019; 134: 127-140.

Dafni U, Tsourti Z, Alatsathianos I. Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries. *Breast Care* 2019; 14 (6): 344-353.

Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn S P, ..., Geiger T, Kammler R, Peters S, Stahel RA, for the Lungscape Consortium. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. *Modern Pathology* 2019; 33 (5): 792-801.

Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. *Ann Oncol.* 2019; 30 (12): 1902-1913.

Wagner A D, Oertelt-Prigione S, Adjei A, Buclin T, Cristina V, Csajka C, Coukos G, Dafni U, Dotto G P, Ducreux M, Fellay J, Haanen J, Hocquet A, Lemmens V, Letsch A, Mauer M, Moehler M, Peters S, Özdemir B C. Gender Medicine and Oncology: A call for learning from each other. Report and consensus of an ESMO Workshop. *Ann Oncol.* 2019; 30 (12): 1914-1924.

Dafni U, Cherny N, De Vries E. Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Relative Clinical Survival Benefit. *JAMA Oncology* 2019; 5 (12): 1807.

Sarivalasis A, Boudousquié C, Balint K, Stevenson BJ, Gannon PO, Iancu EM, Rossier L, Martin Lluesma S, Mathevet P, Sempoux C, Coukos G, Dafni U, Harari A, Bassani-Sternberg M, Kandalaft LE. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. *J Transl Med.* 2019; 17 (1):391.

Molina-Vila MA, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, et al. Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. *J Thorac Oncol.* 2020; 15 (3), 416-425.

Stahel RA, Curioni-Fontecedro A, Rohrmann S, Dafni U, Sandner U, Opitz I, Andratschke N, Franzen D, Dimopoulou G, Matthes KL, Kohler M, Guckenberger M, Weder W. Survival outcome of non-small cell

lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug . **Lung Cancer** 2020; **146**:217-223.

Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Dafni U, de Vries EGE, ..., Scarfò L, Wester R, Zygoura P, Sonneveld P. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. **ESMO Open**. 2020; **5** (1):e000611.

Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, ..., Rabaglio M, O'Brien MER, Stahel RA. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. **J Thorac Oncol**. 2020; **15**(10):1647-1656.

Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O'Brien M, ..., Gasca-Ruchti A, Peters S, Stahel R. A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. **Ann Oncol** 2020; **31** (12), 1734-1745.

Paluch-Shimon S, Cherny NI, de Vries EGE, Dafni U, Piccart MJ, Latino NJ, Cardoso F. Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. **ESMO Open**. 2020; **5** (5):e000743.

Knapen DG, Cherny NI, Zygoura P, Latino NJ, Douillard JY, Dafni U, de Vries EGE, de Groot DJ. Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1. **ESMO Open**. 2020; **5** (5):e000681.

Dafni U, Martín-Lluesma S, Balint K, Tsourti Z, Vervita K, Coukos G, Zaman K, Sarivalasis A, Kandalaf LE. Efficacy of Cancer Vaccines in Breast and Ovarian Selected Gynecological Cancers: A Twenty-Years Systematic Review and Meta-analysis. **Eur J Cancer** 2021;**142**:63-82. Epub 2020 Nov 19.

Dafni U, Zygoura P and Tsourti Z. Statistical Design Flexibility Versus Optimism: The Example of KEYNOTE-604. **IASLC Lung cancer news** 2021 Jan.

Peters S, Filip E, Dafni U, Tufman A, Guckenberger M, ..., Vansteenkiste J, Stahel RA, De Ruyscher D. Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14). **JTO** 2021; **16** (2): 278-288.

Finn SP, Addeo A, Dafni U, Thunnissen E, Bubendorf L, ..., Kerr KM, Peters S, Stahel RA, on behalf of the European Thoracic Oncology Platform Lungscape Investigators. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results from the European Thoracic Oncology Platform Lungscape Project. **JTO** 2021; **16**(6): 990–1002

Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, ..., Zielinski C, Zygoura P, Cherny NI. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. **ESMO Open**. 2021; **6** (3):100117.

Meylan S, Dafni U, Lamothe F, Tsourti Z, Lobritz MA, ..., Calandra T, Pantaleo G, Lazor-Blanchet C. SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. **BMJ open** 2021; **11** (7): e049232.

Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, ..., Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M. Combined, patient-level, analysis of two randomised trials evaluating the addition of

denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOR and AMGEN-249 trials. **Lung cancer 2021; 161:76-85.**

Berghoff AS, Sessa C, Yang JC-H, Tsourti Z, Tsang J, ..., Dimopoulou G, Dafni U, Choo SP, Banerjee S, Bajpai J, Adjei AA, Garrido P. Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies. **ESMO Open 2021; 6 (6):100281.**

Soo RA, Han JY, Dafni U, Cho BC, ..., Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S, ETOP 10-16 BOOSTER Collaborators. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. **Ann Oncol. 2021; S0923-7534(21)04825-0.**

Peters S, Pujol JL, Dafni U, Dómine M, Popat S, ..., Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel RA, Le Pechoux C, De Ruyscher D, ETOP/IFCT 4-12 STIMULI Collaborators. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. **Ann Oncol. 2022; 33 (1):67-79.**

Lazor-Blanchet C, Zygoura P, Dafni U, Lamothe F, Tsourti Z, Lobritz MA, Regina J, Grandbastien B, Fenwick C, Pantaleo G, Calandra T, Meylan S. Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period. **J Infect. 2022; 5:S0163-4453(22)00062-7.**

Pérol M, Felip E, Dafni U, Polito L, Pal N, Tsourti Z, Ton TGN, Merritt D, Morris S, Stahel RA, Peters S. Effectiveness of PD-(L)1 Inhibitors Alone or in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC) With PD-L1–High Expression Using Real-World Data. **Ann Oncol. 2022; 33(5):511-521.**

Razis E, Kassapian M, Andriakopoulou C, Martei YM, Zurn SJ, Hammad N, Romero Y, Dafni U, Ilbawi AM, Trapani D. Essential medicines list in national cancer control plans: a secondary analysis from a global study. **Lancet Oncol. 2022; 23 (3):e144-154.**

Cherny NI, Dafni U, Pentheroudakis G, Piccart M, Zygoura P, Gyawali B, de Vries EGE. “The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores. **ESMO Open 2022; 7 (2):100413.**

Banna GL, Addeo A, Zygoura P, Tsourti Z, Popat S, ..., Dafni U, Peters S, Stahel RA. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial. **Lung Cancer 2022; 169:77-83.**

Dafni U, Soo RA, Peters S, Tsourti Z, Zygoura P, Vervita K, ..., Ruepp B, Rosell R, Stahel RA. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC; a systematic review and meta-analysis. **ESMO Open 2022; 7 (3):100507.**

Castelo-Branco L, Tsourti Z, Gennatas S, ..., Dimopoulou G, Pradervand S, Arnold D, Harrington K, Michielin O, Dafni U, Pentheroudakis G, Peters S, Romano E. COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE). **ESMO Open 2022; 7 (3):100499.**

Felip E, Smit EF, Molina-Vila MA, Dafni U, Massuti B, Berghmans T, De Marinis F, Passiglia F, Dingemans AM C, Cobo M, Viteri S, Britschgi C, Cuffe S, Provencio M, Merkelbach-Bruse S, Andriakopoulou C, Kammler R, Ruepp B, Roschitzki-Voser H, Peters S, Wolf J, Stahel R, on behalf of the ETOP 12-17 ALERT -lung Collaborators. Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial. **Lung Cancer 2022; 172: 94-99.**

Nader-Marta G, Debieu V, Eiger D, Tsourti Z, ..., Piccart M, Dafni U, de Azambuja E. Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study. **Br J Cancer** 2022; 127 (10): 1799-1807.

O'Brien M, Paz-Ares L, Marreaud S, Dafni U, ... Stahel R, Besse B, Peters S. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. **Lancet Oncol.** 2022; 23 (10): 1274-1286.

Bubendorf L, Zoche M, Dafni U, Hendrik Rüschoff J, Savic Prince S, Marti N, Stavrou A, Kammler R, Finn S, Mochb H, Peters S, Stahel R. Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort. **Lung Cancer** 2022; 174: 27-35.

Cortellini, A., Dettorre, G.M., Dafni, U., ..., M., Tabernero, J., Pentheroudakis, G., Gennari, A., Peters, S., Romano, E., Pinato, D.J. Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries **J. Immunother Cancer** 2022; 10 (11), art. no. e005732.

Castelo-Branco, L., Pellat, A., Martins-Branco, D., Valachis, A., Derksen, J.W.G., Suijkerbuijk, K.P.M., Dafni, U., Dellaporta, T., Vogel, A., Prelaj, A., Groenwold, R.H.H., Martins, H., Stahel, R., Bliss, J., Kather, J., Ribelles, N., Perrone, F., Hall, P.S., Dienstmann, R., Booth, C.M., Pentheroudakis, G., Delaloge, S., Koopman, M. ESMO Guidance for Reporting Oncology real-World evidence (GROW **Ann Oncol.** 2023; 34 (12), pp. 1097-1112.

Opitz, I., Bille, A., Dafni, U., ..., M.M., Baird, A.-M., Barr, M.P., Cuffe, S., Gately, K., Thüsen, J.V.D., Passani, S., ETOP Mesoscape and ESTS Consortia. European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database **J. Thorac Oncol.** 2023; 18 (9): 1233-1247.

Kiesewetter, B., Dafni, U., de Vries, E.G.E., Barriuso, J., Curigliano, G., ... , Piccart, M., Raderer, M., Scarfò, L., Trapani, D., Zielinski, C.C., Wester, R., Zygoura, P., Macintyre, E., Cherny, N.I., ESMO-MCBS Working Group and Extended Working Group. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0. **Ann Oncol.** 2023; 34 (9): 734-771.

Martin, P., Tsourti, Z., Ribeiro, J., Castelo-Branco, L., ..., Dafni, U., Peters, S., Pentheroudakis, G., Romano, E.;

COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases. **ESMO Open.** 2023; 8 (3), art. no. 101566.

Zarkavelis, G., Amylidi, A.L., Verbaanderd, C., Cherny, N.I., Metaxas, Y., de Vries, E.G.E., Zygoura, P., Amaral, T., Jordan, K., Strijbos, M., Dafni, U., Latino, N., Galotti, M., Lordick, F., Giuliani, R., Pignatti, F., Pentheroudakis, G.

Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines **ESMO Open.** 2023; 8 (1), art. no. 100604.

Martins-Branco, D., Kassapian, M., Debieu, V., Caparica, R., Eiger, D., Dafni, U., Andriakopoulou, C., El-Abed, S., Ellard, S.L., Izquierdo, M., Vicente, M., Chumsri, S., Piccart-Gebhart, M., Moreno-Aspitia, A., Knop, A.S., Lombard, J., de Azambuja, E.. The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study **Breast Cancer Res Treat.** 2024; 203 (3): 497-509.

Peters, S., Letovanec, I., Mauer, M., Dafni, U., Ejedepang, D., Biernat, W., Bubendorf, L., Warth, A., Pokharel, S., Reinmuth, N., Majem Tarruella, M., Casas-Martin, J., Tsourti, Z., Marti, N., Kammler, R., Danson, S., O'Brien, M., Stahel, R.A. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial **Lung Cancer**. 2023; 175, pp. 141-151.

Martín-Lluesma S, Svane IM, Dafni U, Vervita K, Karlis D, Dimopoulou G, Tsourti Z, Rohaan MW, Haanen JBAG, Coukos G, Efficacy of TIL Therapy in Advanced Cutaneous Melanoma in the Current Immuno-oncology Era: Updated Systematic Review and Meta-analysis, **Ann Oncol.**, 2024 July, ISSN 0923-7534,

Hackshaw A, Fajardo O, Dafni U, Gelderblom H, Garrido P, Siena S, Taylor MH, Bordogna W, Nikolaidis C. Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion–Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting. **JCO Precision Oncology**. 2024 Jan;8(1):e2300334.

Speel EJM, Dafni U, Thunnissen E, Ruschoff JH, Brien CO, Kowalski J, Kerr KM, Bubendorf L, Sansano-Valero I, Joseph L, Kriegsmann M, Navarro A, Monkhorst K, Madsen LB, Hernandez-Losa J, Biernat W, Stenzinger A, Rüland A, Hillen LM, Marti N, Molina-Vila MA, Dellaporta T, Kammler R, Peters S, Stahel RA, Finn SP, Radonic T. ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology platform Lungscape project. **Lung Cancer**, 2024, 107860.

Julian E, Solà-Morales O, Garcia MJ, ..., Dafni U, Bucher HC, Pérez-Valderrama B, Bernardini R, Gianfrate F, Uyl-de Groot CA, Ruof J. The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights Generated at the 2023 Fall Convention and Survey of the European Access Academy J. Mark. **Access Health Policy** 2024; 12 (3), 128-143.

Soo RA, Dafni U, Han J-Y, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Provencio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, Stahel RA; ETOP 10-16 BOOSTER Collaborators. ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial. **Clinical Cancer Research** 2024; 30 (22): 5180–5191.